Cantor Fitzgerald Reiterates Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a report on Friday, August 23rd. Royal Bank of Canada assumed coverage on shares of COMPASS Pathways in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $23.00 price target on the stock. Finally, Canaccord Genuity Group cut their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Price Performance

CMPS stock opened at $6.81 on Monday. The firm has a 50 day simple moving average of $7.11 and a two-hundred day simple moving average of $7.98. The stock has a market cap of $465.67 million, a PE ratio of -2.87 and a beta of 2.27. COMPASS Pathways has a one year low of $5.01 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same period in the prior year, the firm posted ($0.62) EPS. On average, analysts predict that COMPASS Pathways will post -2.35 EPS for the current fiscal year.

Institutional Trading of COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Logos Global Management LP increased its stake in shares of COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after buying an additional 901,050 shares during the period. Affinity Asset Advisors LLC purchased a new position in shares of COMPASS Pathways in the fourth quarter valued at about $4,812,000. PFM Health Sciences LP raised its stake in shares of COMPASS Pathways by 540.7% during the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock valued at $2,964,000 after acquiring an additional 285,890 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock worth $1,593,000 after purchasing an additional 247,500 shares during the period. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of COMPASS Pathways during the second quarter worth about $664,000. Institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.